Pre Eclampsia: Its Effect on Renal, Cardiovascular, Hepatic and Thyroid Functions a Review

Sabitha kandi¹, B Venu Gopal¹, Raj Kumar G¹, MD Rafi¹, T Sudhakar¹, C Ramadevi², Mamatha², Pragna Rao³ and K V Ramana^4,

¹Department of Biochemistry, Chalmeda Anandrao Institute of Medical Sciences, Karimnagar, India

²Department of Obstetrics and Gynaecology, Chalmeda Anandrao Institute of Medical Sciences, Karimnagar, India

³Department of Biochemistry, Kasturba Medical College, Manipal University, Manipal, India

⁴Department of Microbiology, Prathima Institute of Medical Sciences, Karimnagar, India

Cite this paper:
Sabitha kandi, B Venu Gopal, Raj Kumar G, MD Rafi, T Sudhakar, C Ramadevi, Mamatha, Pragna Rao and K V Ramana. Pre Eclampsia: Its Effect on Renal, Cardiovascular, Hepatic and Thyroid Functions a Review. American Journal of Clinical Medicine Research. 2014; 2(6):111-113. doi: 10.12691/ajcmr-2-6-2

Abstract

Preeclampsia is a severe disorder of pregnancy characterized by the development of hypertension and proteinuria, increased vascular resistance and endothelial dysfunction in the mother, altered placental perfusion and restricted fetal growth. There is increased release of soluble growth factor like sFlt 1 from placenta, which decreases the availability of Vascular Endothelial Growth Factor(VEGF) receptors and decreases the availability of endothelial Nitric Oxide synthase. This inturn decreases the diastolic relaxation and endothelial dysfunction, podocyte injury of glomerular cells, increased excretion of podocyte specific proteins in urine leads to proteinuria. Cardiac hypertrophy further complicates the heart function. There is a raise in liver function; soluble factor like tyrosine kinase 1 (sFlt 1) may cause a disturbance in thyroid hormone function, thus prone to thyroid problem during or after pregnancy.

Keywords:
preeclampsia proteinuria cardiac hypertrophy soluble factor like tyrosine kinase 1 (sFlt 1) endothelial dysfunction

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Wagner L.K. Diagnosis and Management of pre eclampsia, American Family Physicians; 2004: 70(12): 2318-2324.
[2]	Prakash J, Pandey L.K, Singh A.K and Kar B. Hypertension in pregnancy, Hospital based study, JAPI; 2006:54:273-278.
[3]	A.K. Rao, K. Daniels, Y. Y. El – Sayed, M. K. Moshesh, and A. B. Caughey, “ Perinatal outcomes among Asian American and Pacific Islander women”. American Journal of Obstetrics and Gynecology, vol. 195, no. 3, pp. 834-838, 2006.
[4]	Elosha Eiland, Chike Nzerue, and Marquetta Faulkner, Preeclampsia 2012, Journal of Pregnancy, vol.2012.
[5]	Maynard Se, Min JY, Merchan J, Lim KH, Li J, Mondal S et. Al., Excess placental soluble fms – like tyrosine kinase 1 (sFlt – 1) may contribute to endothelial dysfunction, hypertension and proteinuria in pre eclampsia. J Clin Invest; 2003;111:649-58.
[6]	Levine Rj, Maynard SE, Qian C, Lim KH, England LJ, Yu KF et.al., Circulating angiogenic factors and the risk of pre eclampsia. N Engl J Med 2004; 350:672-83.
[7]	D. Hui, N. Okun, K. Murphy, J. Kingdom, E. Uleryk, and P.S. Shah, “Combinations of maternal serum markers to predict preeclampsia, small for gestational age, and stillbirth: a systematic review”., Journal of Obstettrics and Gynaecology Cananda, vol.34, no.2, pp. 142-153, 2012.
[8]	S. Venkatesha, M. Toporsian, C. Lam et al., “Soluble endoglin contributes to the pathogenesis of preeclampsia”, Nature Medicine, vol.12, no.6, pp. 642-649, 2006.
[9]	Sibai B.M and Gonzalez R.A. Severe pre eclampsia – eclampsia in young primigravid women : Subsequent pregnancy outcome and remote prognosis, Am Journal Obstet Gynaecol, 1986: 155: 1011-1016.
[10]	D. S. Gelinas, P. N. Bernatchez, S. Rollin, N. G. Bazan, and M. G. Sirois, “Immediate and delayed VEGF – mediated NO synthesis in endothelial cells: role of P13K, PKC and PLC pathways”, British Journal of pharmacology, vol. 137. No. 7, pp. 1021-1030, 2002.
[11]	Robert L. Barbieri, John T. Repke. Medical disorders during pregnancy: Harrison’s principles of internal medicine: chapter 6: volume I: Mc Graw Hill Publishing division; 2005: 32.
[12]	Furuya M, Ishida J, Aoki I, Fukamizu A. Pathophysiology of placentation abnormalities in pregnancy – induced hypertension. Vasc Health Risk Manag. 2008; 4: 101-1313.
[13]	Patten IS, Rana S, Shahul S, Rowe GC, Jang et.al.,. Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. Nature. 2012; 485: 333-338.
[14]	A. Wright, British Journal of Obstetrics and Gynecology 1987; 94: 408-412.
[15]	I. E. Stillman and S. A Karumanchi, “The glomerular injury of preeclampsia”, Journal of the American Society of Nephrology, vol.18, no. 8, pp. 2281-2284, 2007.
[16]	Y Wang, S.Zhao, S.Loyd and L. J. Groome, “Increased urinary excretion of nephrin, podocalyxin, and big – h3 in women with preeclampsia”, American Journal of physiology, vol.30, no.9, pp. F1084 – F1089, 2012.
[17]	Q. Chen, L. Chen, B, Liu et al. “The role of autocrine TGFβ1 in endothelial cell activation induced by phagocytosis of necrotic trophoblasts; a possible role in the pathogenesis of pre eclampsia”, Journal of pathology, vol.221, no.1,pp.87-95, 2010.
[18]	V.C. Sandrim, A. C. T. Palei, I. F. Metzger, V. A. Gomes, R. C. Cavalli, and J. E. Tanus – Santos, “Nitric oxide formation is inversely related to serum levels of antiangiogenic factors soluble fms – like tyrosine kinase 1 and soluble endogline in preeclampsia”, Hypertension, vol.52, no. 2, pp. 402-407, 2008.
[19]	Slowinsk i, T. Neumayer, H.H: stolze, T, Grossing G; Halle, H and Houcher,B 2002. Endothelin system in normal and hypertensive pregnancy, clinical science.103(48); 446s-449.
[20]	Hassan TJ, Jaerey SN, J Pak Med Assoc. 1991; 41(8): 183-5.
[21]	Williams Obstetrics 21st edition.
[22]	Barbara A. Clark, MD, Lisa Halvorson, MD. Am J Obstet Gynecol : 1992; 166: 962-968.
[23]	Lionel J.schewitz. The medical clinics of north America.
[24]	British journal of obstetrics and gynaecology, 1997; 84: 13-21.
[25]	Melchiorre K, Sutherland GR, Baltabaeva A, Liberati M, Thilaganathan B. ‘Maternal cardiac dysfunction and remodeling in women with preeclampsia at term’. Hypertension. 2011 Jan; 57(1): 85-93.
[26]	Mann DL, Bristow MR. mechanisms and models in heart failure: the biomechanical model and beyond. Circulation. 2005; 111: 2837-849.[pub med].
[27]	Bartel DP, Chen CZ. Micromanagers of gene expression: the potentially widespread influence of metazoan mocroRNAs. Nat Rev Genet. 2004; 5: 396-400. [pub med].
[28]	Bartel DP, Micro RNAs: target recognition and regulatory functions. Cell. 2009; 136: 215=233. [PMC free article] [pub med].
[29]	Sayed D, Hong C, Chen IY, Lypowy J, Abdellatif M. MicroRNAs play an essential role in the development of cardiac hypertrophy. Circ res. 2007; 100: 416-424. [pub med].
[30]	Care A, Catalucci D, Felicetti F, Bonci D, Addario A, et al.,. Micro RNA – 133 controls cardiac hypertrophy. Nat Med 2007; 13: 613-618. [pub med].
[31]	Gardner JD, Murray DB, Voloshenyuk TG, Brower GL, Bradley JM et al.,. Estrogen attenuates chronic volume induced structural and functional remodeling in male rat hearts. Am J Physiol Heart Circ Physiol. 2010;298: H497 –H504. [PMC free article] [pub med].
[32]	Otsuka K, Terasaki F, shimomura H, Tsukada B, Horii T, Isomura T et al.,. Enhanced expression of the ubiquitin – proteasome system in the myocardium from patients with dilated cardiomyopathy referred for left ventriculoplasty: an immunohistochemical study with special reference to oxidative stress. Heart vessels. 2010; 25: 474-484. [pub med]
[33]	Burrow and Duffy : Medical complications during pregnancy.
[34]	The new England journal of medicine jan27, 1972.
[35]	Journal of Obstetrics and Gynecology ; 1984; 91: 857-862.
[36]	Churchill D1, Kilby MD, Bignell A, Whittle MJ, Beevers DG Gamma-glutamyl transferase activity in gestational hypertension. Br J Obstet Gynaecol. 1994 Mar; 101(3): 251-3.
[37]	37. Larijani B, Marsoosi V, Aghakhanl S, Moradi A, Hashmipour S. Thyroid hormone alteration in pre-eclamptic women. Gynecol Endocrinol 2004; 18: 97-100.
[38]	38. Richard J Levine, lars J Vatten, Gary L Horowitz,Cong Qian, Pal R Romundstad et al., Pre eclampsia, soluble fms – like tyrosine kinase 1, and the risk of reduced thyroid function: nested case control and population based study. BMJ 2009; 339: b4336.
[39]	Eremina V, Jefferson JA, Kowalewska J, Hochster H, Haas M, et al., VEGF inhibition and renal thrombotic micro angiopathy. N Engl J Med 2008; 358: 1129-36.
[40]	Kamba T, Mc Donald DM. Mechanism of adverse effects of anti – VEGF therapy for cancer 2007; 96: 1788-95.
[41]	Risau W. Development and differentiation of endothelium. Kidney Int 1998; 67: s3-6.
[42]	Kamba T, Tam BY, Hashizume H, Haskell A, Sennino B et al., VEGF dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart irc Physiol 206; 290: H560-76.